Literature DB >> 24004665

Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells.

Paul Greaves1, Andrew Clear, Andrew Owen, Sameena Iqbal, Abigail Lee, Janet Matthews, Andrew Wilson, Maria Calaminici, John G Gribben.   

Abstract

CD4(+) T-helper cells (THs) dominate the classical Hodgkin lymphoma (CHL) microenvironment, but their role is poorly understood. Advances in flow cytometry and immunohistochemistry permit more detailed investigation of this aspect of CHL pathophysiology. To address the hypothesis that the TH-infiltrate, rather than being TH2-enriched, senescent and hypofunctional, is TH1 and activation marker-rich, cytokine-secretory and proliferative, we applied comprehensive flow cytometric immunophenotyping and functional assays of cytokine secretion/proliferation to TH cells from 18 CHL-derived single-cell suspensions (SCSs) compared to reactive lymph nodes (RLNs). CHL-derived TH cells express TH1-associated CXCR3/CCR5 and TNFα/IFNγ/interleukin-2 (IL-2) and less TH2-associated CCR3/CCR4, with no IL-4/IL-13. They lack exhaustion-/suppression-associated PD1, CD57 and terminally differentiated effector memory cells, with more central memory cells, activation-associated partners of Hodgkin Reed Sternberg (HRS) cell-expressed CD30/OX40-L/ICOS-L, and other activation markers. TH cell lines established from CHL and RLN-derived SCSs remain cytokine-secretory. We confirmed and extended these studies using tissue microarray immunohistochemistry (TMA-IHC) from a large CHL tissue bank (n = 122) and demonstrate TH1-associated TBET is abundant in CHL, and TH2-associated CMAF/GATA3 and exhaustion-associated PD1 expressed at significantly lower levels. These molecular insights into the CHL-associated TH offer potential diagnostic, prognostic and pharmacologically modifiable therapeutic targets and do not support the established view of a TH2-enriched, senescent/exhausted, hypofunctional, hypoproliferative infiltrate.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24004665      PMCID: PMC5291299          DOI: 10.1182/blood-2013-06-508044

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

Review 1.  T-bet in disease.

Authors:  Vanja Lazarevic; Laurie H Glimcher
Journal:  Nat Immunol       Date:  2011-06-20       Impact factor: 25.606

2.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

3.  Infiltration of Th1 and Th2 lymphocytes around Hodgkin and Reed-Sternberg (H&RS) cells in Hodgkin disease: Relation with expression of CXC and CC chemokines on H&RS cells.

Authors:  Koichi Ohshima; Takeshi Tutiya; Takahiro Yamaguchi; Keiko Suzuki; Junji Suzumiya; Chika Kawasaki; Seiji Haraoka; Masahiro Kikuchi
Journal:  Int J Cancer       Date:  2002-04-01       Impact factor: 7.396

4.  Tumor microenvironment composition in pediatric classical Hodgkin lymphoma is modulated by age and Epstein-Barr virus infection.

Authors:  Mário Henrique M Barros; Gabriela Vera-Lozada; Fernando A Soares; Gerald Niedobitek; Rocio Hassan
Journal:  Int J Cancer       Date:  2011-12-21       Impact factor: 7.396

5.  Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells.

Authors:  Tomás Alvaro; Marylène Lejeune; Ma Teresa Salvadó; Ramón Bosch; Juan F García; Joaquín Jaén; Alison H Banham; Giovanna Roncador; Carlos Montalbán; Miguel A Piris
Journal:  Clin Cancer Res       Date:  2005-02-15       Impact factor: 12.531

6.  Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma.

Authors:  Sabine Schreck; Daniela Friebel; Maike Buettner; Luitpold Distel; Gerhard Grabenbauer; Lawrence S Young; Gerald Niedobitek
Journal:  Hematol Oncol       Date:  2009-03       Impact factor: 5.271

7.  Common and differential chemokine expression patterns in rs cells of NLP, EBV positive and negative classical Hodgkin lymphomas.

Authors:  Ewerton M Maggio; Anke Van Den Berg; Lydia Visser; Arjan Diepstra; Joust Kluiver; Roelke Emmens; Sibrand Poppema
Journal:  Int J Cancer       Date:  2002-06-10       Impact factor: 7.396

Review 8.  Immune escape mechanisms in Hodgkin's disease.

Authors:  S Poppema; M Potters; L Visser; A M van den Berg
Journal:  Ann Oncol       Date:  1998       Impact factor: 32.976

9.  Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.

Authors:  A Belldegrun; L M Muul; S A Rosenberg
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

10.  Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s.

Authors:  R Bonecchi; G Bianchi; P P Bordignon; D D'Ambrosio; R Lang; A Borsatti; S Sozzani; P Allavena; P A Gray; A Mantovani; F Sinigaglia
Journal:  J Exp Med       Date:  1998-01-05       Impact factor: 14.307

View more
  49 in total

Review 1.  The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes.

Authors:  Alexander Marx; John K C Chan; Jean-Michel Coindre; Frank Detterbeck; Nicolas Girard; Nancy L Harris; Elaine S Jaffe; Michael O Kurrer; Edith M Marom; Andre L Moreira; Kiyoshi Mukai; Attilio Orazi; Philipp Ströbel
Journal:  J Thorac Oncol       Date:  2015-10       Impact factor: 15.609

2.  Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment.

Authors:  Fathima Zumla Cader; Ron C J Schackmann; Xihao Hu; Kirsty Wienand; Robert Redd; Bjoern Chapuy; Jing Ouyang; Nicole Paul; Evisa Gjini; Mikel Lipschitz; Philippe Armand; David Wu; Jonathan R Fromm; Donna Neuberg; X Shirley Liu; Scott J Rodig; Margaret A Shipp
Journal:  Blood       Date:  2018-06-07       Impact factor: 22.113

Review 3.  Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results.

Authors:  Anas Younes; Stephen M Ansell
Journal:  Semin Hematol       Date:  2016-05-13       Impact factor: 3.851

Review 4.  Haematological malignancies: at the forefront of immunotherapeutic innovation.

Authors:  Pavan Bachireddy; Ute E Burkhardt; Mohini Rajasagi; Catherine J Wu
Journal:  Nat Rev Cancer       Date:  2015-03-19       Impact factor: 60.716

5.  The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative.

Authors:  Sanjay S Patel; Jason L Weirather; Mikel Lipschitz; Ana Lako; Pei-Hsuan Chen; Gabriel K Griffin; Philippe Armand; Margaret A Shipp; Scott J Rodig
Journal:  Blood       Date:  2019-12-05       Impact factor: 22.113

6.  High proportions of PD-1+ and PD-L1+ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome.

Authors:  Peter Hollander; Peter Kamper; Karin Ekstrom Smedby; Gunilla Enblad; Maja Ludvigsen; Julie Mortensen; Rose-Marie Amini; Stephen Hamilton-Dutoit; Francesco d'Amore; Daniel Molin; Ingrid Glimelius
Journal:  Blood Adv       Date:  2017-08-08

Review 7.  Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?

Authors:  Fabienne McClanahan; Thomas G Sharp; John G Gribben
Journal:  Haematologica       Date:  2016-10       Impact factor: 9.941

Review 8.  The role of T cells in the microenvironment of Hodgkin lymphoma.

Authors:  Frederik Wein; Ralf Küppers
Journal:  J Leukoc Biol       Date:  2015-08-28       Impact factor: 4.962

Review 9.  Immune Modulation in Hematologic Malignancies.

Authors:  Madhav V Dhodapkar; Kavita M Dhodapkar
Journal:  Semin Oncol       Date:  2015-06-03       Impact factor: 4.929

Review 10.  The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints.

Authors:  Santosha Vardhana; Anas Younes
Journal:  Haematologica       Date:  2016-07       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.